Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Medicines Company has reported superior clinical outcomes and fewer cardiac deaths in heart attack patients undergoing angioplasty compared to a more complex treatment regimen for its anti-clotting agent Angiomax in a global trial.
Subscribe to our email newsletter
The Horizons AMI trial compared Angiomax to heparin plus a platelet glycoprotein IIb/IIIa inhibitor (GPI) in more than 3,600 patients presenting with a heart attack. Horizons AMI demonstrated the efficacy of Angiomax in angioplasty patients with the most severe form of heart attack, ST-elevation myocardial infarction.
At 30 days, compared to heparin plus GPI, Angiomax reduced the incidence of net adverse clinical events, a composite of major adverse cardiac events or major bleeding, by 24%; curbed major bleeding by 40%; demonstrated comparable rates of major adverse cardiac events and reduced the incidence of cardiac-related mortality by 38%.
John Kelley, president and chief operating officer of Medicines Company, said: “The Horizon AMI results clearly demonstrate better clinical outcomes with Angiomax in heart attack patients. Findings from multiple global studies are remarkably consistent and show Angiomax improves outcomes across the entire spectrum of patients treated in the cardiac cath lab. Given these results, we anticipate greater uptake of Angiomax by physicians worldwide.”